Press Releases

For decades, pancreatic cancer has remained one of the most difficult cancers to treat. Too often diagnosed late and resistant to many standard therapies, it has long demanded new thinking, […]

UPDATE (5/1/2026): The FDA has just authorized expanded access to daraxonrasib, a targeted therapy designed to treat KRAS-driven cancers. For the first time, this treatment is now available outside of […]

The Lustgarten Foundation’s annual International Women’s Day symposium, The Power of Persistence: Women Transforming Cancer Research and Care, highlights women’s critical role in advancing innovation in the fight against cancer. Co-chaired […]

We were disappointed to learn that the Galleri multi-cancer early detection (MCED) test, developed by GRAIL, did not meet the primary endpoint in its large randomized trial conducted in partnership […]

While cancer mortality rates in the United States have steadily declined over recent decades, a group of recalcitrant cancers remains stubbornly lethal. For diseases like pancreatic, ovarian, and upper GI […]

WHY EARLY DETECTION IN PANCREATIC CANCER CAN’T WAIT For decades, pancreatic cancer has been defined by late diagnosis and limited options. The disease often progresses silently and aggressively, with symptoms […]

WHAT KRAS MEANS AND WHY IT MATTERS KRAS is what scientists call an oncogene – a gene that, when mutated, can promote uncontrolled cell growth and lead to cancer. In […]

COLD SPRING HARBOR, N.Y., Oct 10, 2025 – The Lustgarten Foundation, the world’s largest private funder of pancreatic cancer research, convened its annual Scientific Advisory Board (SAB) Meeting on October […]